Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail.

111 Similarly, another randomized placebo-controlled trial with NASH patients with F1-F3 fibrosis with emricasan (5 mg or 50 mg) for 72 weeks did not improve liver histology in patients with NASH fibrosis and showed a trend towards worsening of fibrosis and ballooning. 112 This drug is unlikely to hold promise.

also in 53,322 other papers

113 A follow-up study that used magnetic resonance imaging (MRI)-based evaluation of fibrosis assessment in patients receiving selonsertib showed a positive trend warranting further investigations. 114 Two subsequent randomized, double-blind, placebo-controlled, phase 3 trials of selonsertib in patients with NASH and bridging fibrosis F3 (STELLAR-3 trial) or compensated cirrhosis (STELLAR-4 trial) were conducted, wherein patients were randomized 2:2:1 to receive selonsertib at 18 mg, selonsertib at 6 mg, or placebo once daily for 48 weeks. 115 Neither of these trials met the primary endpoint, and no improvement in fibrosis was noted.

also in 11,005 other papers